CLRB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
7.2M
+24.2%
5.8M
+1.8%
5.7M
+17.3%
4.9M
-19.7%
6.0M
R&D
4.6M
+51.5%
3.0M
-4.8%
3.2M
+25.2%
2.5M
+5.6%
2.4M
SG&A
2.6M
-5.3%
2.8M
+10.1%
2.5M
+8.8%
2.3M
-36.2%
3.6M
Operating Income
-7196012
-24.2%
-5793942
-1.8%
-5690629
-17.3%
-4850696
+19.7%
-6037529
EBITDA
-7160488
-21.3%
-5903960
-4.7%
-5641168
-17.6%
-4798419
+19.8%
-5981965
Net Income
-6930653
-22.6%
-5653946
-6.8%
-5295221
-19.2%
-4443877
+18.4%
-5447911
EPS (Basic)
$-0.57
+57.1%
$-1.33
-3.9%
$-1.28
+9.2%
$-1.41
+58.4%
$-3.39
EPS (Diluted)
$-0.57
+57.1%
$-1.33
-3.9%
$-1.28
+9.2%
$-1.41
+58.4%
$-3.39
Shares (Diluted)
12.2M
+188.5%
4.2M
+2.8%
4.1M
+30.5%
3.2M
+96.5%
1.6M
Cellectar Biosciences INC NEW (CLRB) โ€” Financials